04.21.2022
Hebrew SeniorLife: “Jazz Singer Donna Byrne Kicks off 23rd Year of Orchard Cove Scholarship Fund”
04.12.2022
Akston Biosciences: “Akston Biosciences CEO to Present at the World Vaccine Congress: Akston’s AKS-452 COVID-19 vaccine is shortlisted for Best New Vaccine Technology/Platform in Vaccine Industry Excellence (ViE) Awards”
04.07.2022
Akston Biosciences: “Akston Biosciences Doses First Volunteers in Phase II/III Clinical Trial of Low Cost, Shelf Stable COVID-19 Vaccine”
03.31.2022
Hebrew SeniorLife: “Researchers develop scoring tool to measure severity of delirium: Severity scores can guide patient-centered care, study suggests”
Akston Biosciences: “Akston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster”
03.17.2022
Akston Biosciences: “Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries”
03.08.2022
Hebrew SeniorLife: “Hebrew SeniorLife Receives Hospice Care Award: Hebrew SeniorLife Hospice Care, Offered in 16 Communities, is Recognized for Bringing Meaning and Fulfillment in Final Stages of Life”
03.07.2022
Hebrew SeniorLife: “Hebrew SeniorLife Named An Age-Friendly Health System: Institute of Healthcare Improvement Recognized Hebrew Rehabilitation Center’s Campuses in Roslindale and Dedham”
03.03.2022
Hebrew SeniorLife: “Study Finds Geriatric Depression Can Be Treated By Transcranial Magnetic Stimulation”
02.28.2022
Hebrew SeniorLife: “Financing Closes on Simon C. Fireman Expansion in Randolph: Construction Begins This Week on 45 Affordable Senior Homes with Supportive Services in a Passive House-Designed Building”
02.24.2022
Hebrew SeniorLife: “9 Leyland, First Affordable Senior Housing in Upham’s Corner, Underway: Development and Management Partnership between DBEDC and Hebrew SeniorLife Supports Seniors to Age Well in Community”
02.08.2022
Akston Biosciences: “Akston Biosciences Announces Publication in Vaccine of Positive Data for a Room Temperature Protein Subunit COVID-19 Vaccine: Shelf stable for at least 6 months, the low-cost SARS-CoV-2 vaccine can be efficiently manufactured anywhere in the world using abundant existing infrastructure”
